NDC 0078-0827-61 Beovu

Brolucizumab

  1. Labeler Index
  2. Novartis Pharmaceuticals Corporation
  3. 0078-0827
  4. NDC Package Code: 0078-0827-61 Beovu

NDC Package Code 0078-0827-61

The NDC Code 0078-0827-61 is assigned to a package of 1 vial, single-dose in 1 carton > .05 ml in 1 vial, single-dose of Beovu, a human prescription drug labeled by Novartis Pharmaceuticals Corporation. The product's dosage form is injection, solution and is administered via intravitreal form.This product is billed per "ML" milliliter and contains an estimated amount of 0.05 billable units per package.

Field Name Field Value
NDC Code 0078-0827-61
Package Description 1 VIAL, SINGLE-DOSE in 1 CARTON > .05 mL in 1 VIAL, SINGLE-DOSE
Proprietary Name Beovu What is the Proprietary Name?
The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
Non-Proprietary Name Brolucizumab What is the Non-Proprietary Name?
The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
11-Digit NDC Billing Format 00078082761 NDC Format for Billing
For insurance billing purposes the Centers for Medicare & Medicaid Services (CMS) created an 11 digit NDC derivative identifier. If the NDC Package code is less than 11 digits the code must be padded with leading zeros. The leading zeros must be added to the appropriate segment to create a 5-4-2 configuration.
Billing Unit ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
Estimated Billable Units per Package 0.05 ML
RxNorm Crosswalk2204920, 2204925, 2602276 and 2602279 - RxCUI What is RxNorm?
The RxNorm crosswalk provides a normalized naming system for generic and branded drugs by assigning unique concept identifiers (RxCUI) to each NDC.
Product Type Human Prescription Drug What kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
Labeler Name Novartis Pharmaceuticals Corporation
Dosage Form Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route(s)
  • Intravitreal - Administration within the vitreous body of the eye.
Active Ingredient(s)
  • BROLUCIZUMAB 6 mg/.05mL
Sample Package No Sample Package?
This field Indicates whether this package is a sample packaging or not.
Marketing Category BLA - A product marketed under an approved Biologic License Application. What is the Marketing Category?
Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
FDA Application Number BLA761125 What is the FDA Application Number?
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Start Marketing Date 10-07-2019 What is the Start Marketing Date?
This is the date that the labeler indicates was the start of its marketing of the drug product.
Listing Expiration Date 12-31-2023 What is the Listing Expiration Date?
This is the date when the listing record will expire if not updated or certified by the product labeler.
Exclude Flag N What is the NDC Exclude Flag?
This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions ("Y"), or because the listing certification is expired ("E"), or because the listing data was inactivated by FDA ("I"). Values = "Y", "N", "E", or "I".

NDC Code Structure

  • 0078 - Novartis Pharmaceuticals Corporation
    • 0078-0827 - Beovu
      • 0078-0827-61 - 1 VIAL, SINGLE-DOSE in 1 CARTON

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the disclaimer below.

NDC HCPCS Crosswalk

This crosswalk is intended to help the public understand which drug products (identified by NDCs) are assigned to which HCPCS billing codes.

NDC 0078-0827-61 HCPCS crosswalk information with package details and bill units information.

NDC Billing CodeHCPCS CodeHCPCS Code Desc.DosagePackage SizePackage QuantityBillable UnitsBillable Units / Pkg
00078082761J0179Inj, brolucizumab-dbll, 1 mg1 MG0.05166

* Please review the disclaimer below.

Other Product Packages

The following packages are also available for Beovu with product NDC 0078-0827.

NDC Package CodePackage Description
0078-0827-601 SYRINGE, GLASS in 1 CARTON > .05 mL in 1 SYRINGE, GLASS
0078-0827-981 SYRINGE, GLASS in 1 CARTON > .05 mL in 1 SYRINGE, GLASS
0078-0827-991 VIAL, SINGLE-DOSE in 1 CARTON > .05 mL in 1 VIAL, SINGLE-DOSE

* Please review the disclaimer below.